Pomalidomide-amino-PEG3-NH2 is primarily used in the development of targeted drug delivery systems. Its structure allows for the conjugation of pomalidomide, a potent immunomodulatory drug, to other molecules or nanoparticles, enhancing its therapeutic potential. This compound is particularly valuable in cancer therapy, where it can be utilized to create prodrugs or antibody-drug conjugates (ADCs) that selectively deliver pomalidomide to cancer cells, minimizing off-target effects and reducing systemic toxicity. Additionally, the PEG3 spacer improves solubility and stability, ensuring better pharmacokinetics and bioavailability. It is also employed in research to study protein degradation pathways, particularly in the context of cereblon-mediated degradation, which is critical for understanding and treating multiple myeloma and other malignancies.